Lercanidipinhydrochlorid Polpharma

Lercanidipine Hydrochloride, the active ingredient in Lercanidipinhydrochlorid Polpharma, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipinhydrochlorid Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict Good Manufacturing Practice guidelines. Our distribution network ensures reliable delivery to healthcare providers across multiple continents, supporting consistent patient access to essential antihypertensive therapy.

Lercanidipine Hydrochloride is indicated for the treatment of primary (essential) hypertension, a condition characterized by chronically elevated arterial pressure.

- Hypertension: lowers systolic and diastolic blood pressure by selectively relaxing arterial smooth muscle, thereby decreasing peripheral vascular resistance and improving overall hemodynamic stability in adult patients. - Essential hypertension: offers consistent blood pressure reduction, contributing to decreased risk of stroke and myocardial infarction in patients with primary hypertension. - Isolated systolic hypertension: provides effective blood pressure control in elderly patients with predominant systolic elevation.

Lercanidipine Hydrochloride may cause a range of adverse reactions. Patients should be aware of both common and less frequent but serious events.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling, typically of the ankles or lower legs. - Dizziness or light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate without accompanying chest pain. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzyme elevations. - Life‑threatening arrhythmias: irregular heart rhythms requiring urgent care. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Lercanidipine Hydrochloride, clinicians should consider several safety aspects.

- Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Gradual dose adjustments: avoid abrupt discontinuation to prevent rebound hypertension. - Hepatic impairment: use with caution in patients with liver disease, as metabolism may be reduced. - Elderly patients: start at lower doses due to increased sensitivity to vasodilatory effects. - Concomitant CYP3A4 inhibitors: monitor for increased plasma concentrations. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lercanidipine plasma levels, increasing risk of hypotension. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure, reducing antihypertensive effect.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure‑lowering effect may cause excessive hypotension. - Grapefruit juice: can increase lercanidipine concentrations modestly. - Non‑dihydropyridine calcium channel blockers: may enhance cardiac conduction effects. - Beta‑blockers: combined use may lead to bradycardia. - Diuretics: may exacerbate electrolyte disturbances, especially potassium loss.